Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26765093 | 0.91 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14CHRM2 | |
| SCHEMBL24011155 | 0.89 | CYP2C9 (0.51) | CYP2C9CYP2C19HTR2BMAPK14CHRM2 | |
| SCHEMBL24011183 | 0.88 | NAMPT (0.59) | CYP2C9HTR2BNAMPTKEAP1NFE2L2 | |
| SCHEMBL24011100 | 0.87 | CYP2C9 (0.49) | CYP2C9CYP2C19HTR2BMAPK14CHRM2 | |
| SCHEMBL24011095 | 0.87 | NAMPT (0.51) | CYP2C9CYP2C19HTR2BMAPK14CHRM2 | |
| SCHEMBL26633804 | 0.84 | NAMPT (0.56) | CYP2C9HTR2BNAMPTKEAP1NFE2L2 | |
| SCHEMBL24011238 | 0.83 | ALDH1A1 (0.57) | CYP2C9CYP2C19HTR2BMAPK14CHRM2 | |
| SCHEMBL26765090 | 0.81 | NAMPT (0.50) | CYP2C9CYP2C19HTR2BMAPK14NAMPT | |
| SCHEMBL24011347 | 0.80 | CYP2C9 (0.51) | CYP2C9CYP2C19HTR2BMAPK14CHRM2 | |
| SCHEMBL24011315 | 0.79 | NAMPT (0.47) | CYP2C9CYP2C19HTR2BMAPK14CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115843295-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CYP2C9 1551/4885CYP2C19 1361/4885HTR2B 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.